Video
Dr. Mamdani on Evaluating the Immunogenicity of STK11/TP53 Co-Mutations in NSCLC
Author(s):
Hirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.
Hirva Mamdani, MD, thoracic oncologist, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer (NSCLC).
Over the past few years, the paradigm of NSCLC treatment has shifted to include checkpoint inhibitors, which have improved outcomes for many patients, Mamdani says. However, not all patients respond to checkpoint inhibitors. Moreover, the development of primary and acquired resistance remains a significant challenge with checkpoint inhibitor therapy, Mamdani says.
STK11 mutations have been identified as a prevalent driver of primary resistance to immunotherapy in NSCLC, Mamdani says. As such, research efforts are aimed at identifying subsets of immunogenic STK11-mutated NSCLC that could respond to checkpoint inhibitors.
